1,484 results on '"Peters, Godefridus J."'
Search Results
52. Supplementary Figure 1 from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
53. Supplementary Figure Legend from Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells
54. The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs: Exploring Potential Mechanisms of Resistance
55. Data from Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
56. Supplementary Fig. S1 from Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
57. Supplementary Data from Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
58. Supplementary Figures 1-3 from Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance
59. Supplementary Data from Trifluorothymidine Resistance Is Associated with Decreased Thymidine Kinase and Equilibrative Nucleoside Transporter Expression or Increased Secretory Phospholipase A2
60. Supplementary Figure 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
61. Data from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
62. Supplementary Methods from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
63. Supplementary Figure 3 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
64. Supplementary Figure 8 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
65. Supplementary Figure 6 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
66. Supplementary Figure 4 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
67. Supplementary Figure 7 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
68. Supplementary Figures 1-5 from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
69. Supplementary Methods from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
70. Data from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
71. Supplementary Video from MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
72. Supplementary Figure Legend from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
73. Supplementary Figure 5 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
74. Supplementary Video 1 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
75. Supplementary Figure 2 from Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met–driven Pancreatic Carcinoma
76. Supplementary Appendix and Figure 1 from Expression Microarray Analysis and Oligo Array Comparative Genomic Hybridization of Acquired Gemcitabine Resistance in Mouse Colon Reveals Selection for Chromosomal Aberrations
77. Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action
78. Comment on: Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis
79. Cytosine Arabinoside : Metabolism, Mechanisms of Resistance, and Clinical Pharmacology
80. Gemcitabine : Mechanism of Action and Resistance
81. Clinical Activity of Gemcitabine as a Single Agent and in Combination
82. Folate receptors and transporters: biological role and diagnostic/therapeutic targets in cancer and other diseases
83. Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells
84. Discovery of anticancer agents with c-Met inhibitory potential by virtual and experimental screening of a chemical library
85. Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
86. Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth
87. Lactate Dehydrogenase and its clinical significance in pancreatic and thoracic cancers
88. The potential of multi-compound nanoparticles to bypass drug resistance in cancer
89. Glutamate and α-ketoglutarate: key players in glioma metabolism
90. Obituary to Lynette Fairbanks, PhD.
91. Hollow Fiber Assay
92. Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer
93. Author response: Destabilizers of the thymidylate synthase homodimer accelerate its proteasomal degradation and inhibit cancer growth
94. Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer☆
95. Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective
96. Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment
97. Molecular Mechanisms Underlying the Antitumor Activity of 3-Aminopropanamide Irreversible Inhibitors of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer
98. Thymidylate Synthase Inhibition Induces P53 Dependent and Independent Cell Death
99. Thymidine Phosphorylase in Angiogenesis and Drug Resistance : Homology with platelet-derived endothelial cell growth factor
100. The Role of Deoxycytidine Kinase in Gemcitabine Cytotoxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.